Blar i NTNU Open på forfatter "Grønberg, Bjørn Henning"
-
Modifiable factors affecting older patients' quality of life and physical function during cancer treatment
Kirkhus, Lene; Harneshaug, Magnus; Saltyte Benth, Jurate; Grønberg, Bjørn Henning; Rostoft, Siri; Bergh, Sverre; Hjermstad, Marianne Jensen; Selbæk, Geir; Wyller, Torgeir Bruun; Kirkevold, Øyvind; Borza, Tom; Saltvedt, Ingvild; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2019)Background Maintaining physical function and quality of life (QoL) are prioritized outcomes among older adults. We aimed to identify potentially modifiable factors affecting older patients' physical function and QoL ... -
Muscle mass and association to quality of life in non-small cell lung cancer patients
Bye, Asta; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Grønberg, Bjørn Henning; Baracos, Vickie E.; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2017)Background Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle ... -
Mutasjonstesting ved ikke-småcellet lungekreft
Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Peer reviewed; Journal article, 2012)BAKGRUNN. Epidermal vekstfaktor-reseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer ... -
Onkologisk behandling av stadium I-III ikke-småcellet lungekreft ved St. Olavs hospital i perioden 2010-2014
Mathisen, Ingeborg Lund (Master thesis, 2016)Mål: Å undersøke resultatet av høydosert strålebehandling gitt til inoperable pasienter med stadium I-‐III ikke-‐småcellet lungekreft ved kreftklinikken, St. Olavs Hospital. Hvordan er bivirkningene, responsen, responsvarighet ... -
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Eide, Inger Johanne Zwicky; Stensgaard, Simone; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Sørensen, Boe Sandahl; Brustugun, Odd Terje (Peer reviewed; Journal article, 2022)Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 ... -
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Eide, Inger Johanne; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Brustugun, Odd Terje (Peer reviewed; Journal article, 2020)Objectives In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of ... -
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; HORNSLIEN, KJERSTI; Madebo, Tesfaye; Langer, Seppo W.; Schytte, Tine; Risum, Signe; Tsakonas, Georgios; Nyman, Jan; Engleson, Jens; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2022)Objectives In a randomized phase II trial, twice daily (BID) thoracic radiotherapy (TRT) of 60 Gy/40 fractions improved survival compared with 45 Gy/30 fractions in limited stage small-cell lung cancer (LS SCLC). Notably, ... -
Pemetrexed in the treatment of advanced lung cancer
Grønberg, Bjørn Henning (Doktoravhandlinger ved NTNU, 1503-8181; 2010:48, Doctoral thesis, 2010)PEMETREXED SOM BEHANDLING AV AVANSERT LUNGEKREFT Lungekreft er den kreftsykdom som tar flest liv. I Norge er det ca. 2500 nye tilfeller, og flere enn 2000 dør årlig av sykdommen. Ca. 17 % har småcellet lungekreft. De ... -
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial
Malmström, Annika; Poulsen, Hans Skovgaard; Grønberg, Bjørn Henning; Stragliotto, Giuseppe; Hansen, Steinbjørn; Asklund, Thomas; Holmlund, Birgitta; Lysiak, Malgorzata; Dowsett, Joseph; Kristensen, Bjarne Winther; Söderkvist, Peter; Rosell, Johan; Henriksson, Roger (Journal article; Peer reviewed, 2017)Introduction: A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We ... -
Prognostic and predictive factors in limited disease small-cell lung cancer
Valan, Christine Damgaard (Doctoral theses at NTNU;2020:203, Doctoral thesis, 2020)Lung cancer is the most common type of cancer and the leading cause of cancer related deaths. Small cell lung cancer (SCLC) is one of two main types of lung cancer. Concurrent chemoradiotherapy is recommended for SCLC if ... -
The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study
Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Berg, Thomas; Halvorsen, Tarje Onsøien; Ottestad, Anine Larsen; Lund-Iversen, Marius; Brustugun, Odd; Førde, Dagny; Paulsen, Erna-Elise; Donnem, Tom; Andersen, Sigve; Grønberg, Bjørn Henning; Richardsen, Elin (Peer reviewed; Journal article, 2021)Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate ... -
Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Ottestad, Anine Larsen; Dale, Vibeke Grotnes; Richardsen, Elin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantication of nucleic acid sequences. We used absolute quantication of mutated v-Ki-ras2 Kirsten rat sarcoma viral oncogene ... -
The prognostic value of KRAS in circulating cell-free DNA and tumour tissue in patients with non-small cell lung cancer
Wahl, Sissel Gyrid Freim (Doctoral theses at NTNU;2021:315, Doctoral thesis, 2021) -
Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
Stokke, Kristin; Sandvei, Marie Søfteland; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2022)Background: The Glasgow prognostic score (GPS) is an established inflammatory prognostic index in cancer patients. Most studies have only measured GPS at baseline (B-GPS). Effective cancer therapy may reduce inflammation, ... -
Quality of life in patients with advanced non-small-cell lung cancer
Kristensen, Are Korsnes (Doctoral theses at NTNU;2020:410, Doctoral thesis, 2020)Livskvalitet hos pasienter med lungekreft Lungekreft er den kreftformen som tar flest liv. Pasienter med lungekreft har ofte symptomer fra sykdommen, samtidig som de kan oppleve plagsomme bivirkninger fra behandling. ... -
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2016)Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented – probably mainly ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Reasons for prolonged time for diagnostic workup for stage I-II lung cancer and estimated effect of applying an optimized pathway for diagnostic procedures
Stokstad, Trine; Sørhaug, Sveinung; Amundsen, Tore; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2019)Background:Minimizing the time until start of cancer treatment is a political goal. In Norway, the target time forlung cancer is 42 days. The aim of this study was to identify reasons for delays and estimate the effect on ... -
Screening for frailty among older patients with cancer using blood biomarkers of inflammation
Harneshaug, Magnus; Kirkhus, Lene; Saltyte Benth, Jurate; Grønberg, Bjørn Henning; Bergh, Sverre; Whist, Jon Elling; Rostoft, Siri; Jordhøy, Marit Slaaen (Peer reviewed; Journal article, 2018)As frailty is associated with inflammation, biomarkers of inflammation may represent objective measures that could facilitate the identification of frailty. Glasgow prognostic score (GPS), combines C-reactive protein (CRP) ... -
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Brustugun, Odd Terje; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helbekkmo, Nina; Aanerud, Marianne; Grimsrud, Tom Kristian; Helland, Åslaug; Møller, Bjørn; Nilssen, Yngvar; Strand, Trond-Eirik; Solberg, Steinar (Journal article; Peer reviewed, 2018)Introduction There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are ...